Imagia Canexia Health, Inc.

Based in Montréal, Canada, and founded in 2022, Imagia Canexia Health, Inc. was formed through a merger of Imagia Cybernetics, an AI-healthcare company that accelerates oncology solutions, and Canexia Health, an oncology company that streamlines complex cancer genomic information which allows oncologists to identify optimal treatment selection and patient monitoring. In February 2022, Imagia Canexia Health raised CAD 20 million in venture funding from returning investors BDC Capital, PacBridge Capital Partners, and new investor Desjardins Capital. Additionally, Imagia and Canexia are integrated with 20 hospital systems and reference labs globally.

And, the company is led by CEO, James Lumsdaine. Imagia Canexia Health offers an ICH Health software platform, tissue and liquid assays, and expert clinical services. Imagia Canexia Health Insights Platform provides analysis from targeted NGS data which is analyzed to identify genomic variants and recommend treatment options for individual cancer patients. Find It® & Fusions are amplicon-based NGS panels for the detection of genomic mutations and gene fusions events in solid tumor tissue.

Lastly, the Plasma Follow It® panel detects mutations in plasma. The company has expertise in genomics-based cancer assays, bioinformatics, and machine learning. Its integrated solutions leverage AI-based informatics for treatment selection, and patient monitoring, and provides clinical laboratories support to bring testing in-house. The investment in 2022 supported the merger between Imagia Cybernetics Inc.

and Canexia Health, Inc. and it will accelerate access to genomics-based testing for cancer treatment.